



Marina Klein

Canada

Regional Representative – USA and Canada – IAS Executive Committee

Dr. Marina Klein is a Professor of Medicine at McGill University, in Montreal, Quebec, Canada in the Division of Infectious Diseases/Chronic Viral Illnesses Service. She graduated from McGill Medical School (1991) and received her training in Internal Medicine at the Royal Victoria Hospital in Montreal. She completed a research fellowship in Infectious Diseases at the University of Minnesota in 1998 and then returned to McGill University where she received a Master's degree in Epidemiology and Biostatistics (2003). Her clinical interests focus on the treatment of patients with HIV and chronic viral hepatitis. She holds a Tier 1 Canada Research Chair in Clinical and Epidemiologic Studies of Chronic Viral Infections in Vulnerable Populations and has led a Canadian Institutes of Health Research (CIHR) funded prospective cohort study of over 1800 HIV-HCV co-infected patients to study the interaction of these chronic viral infections in a translational research program for over 15 years. She has been a principal investigator in several clinical trials of HIV-HCV coinfection and has worked towards gaining access to liver transplantation for co-infected people in Canada. She is also involved in a number of observational epidemiologic research collaborations (NA-ACCORD and CANOC) focused on understanding long-term clinical and treatment outcomes in HIV and HIV-HCV co-infection, where she has assumed a leadership role in scientific steering committees.

Dr. Klein has been active in the Canadian HIV Research community as a previous member of the Canadian Association of HIV Research governing council and as a member of the CIHR HIV/AIDS Research Advisory Committee. She is National Co-Director of the CIHR-CTN. She is also a mentor in the Canadian Network for Hepatitis C and has worked with the Canadian Treatment Action Council.

Dr. Klein's work with the Canadian Co-Infection cohort has highlighted the extent to which vulnerabilities and co-morbidities are linked in negatively impacting health outcomes. This has led her to establish a research agenda focused on developing and implementing novel care models with the goal of improved diagnosis, management and increased access to treatment for vulnerable populations affected by HIV and HIV-HCV co-infection. Given the particular impact of co-infections on Indigenous communities, she has been working to establish collaborations with indigenous researchers and community members to scale up and evaluate HIV and HCV testing on reserve in Saskatchewan. She sits on the executive committee of the IAS, is co-leader of the IAS Co-Infections working group and has served as Co-chair of the International HIV-Hepatitis Co-Infection Meetings from 2015-2017.